The review also noted that Phase 2, based on studies done, can be incorporated in food and beverage products “without losing activity or altering the appearance, texture, or taste of food.”
Phase 2 Carb Controller, a proprietary white bean extract from Pharmachem (Kearny, NJ) may induce weight loss and reduce spikes in blood sugar caused by carbohydrates, according to a review of more than a dozen studies published in Nutrition Journal.
“Phase 2 Carb Controller has demonstrated the ability to cause weight loss with doses of 500 to 3000 mg per day, in either a single dose, or in divided doses. It also has the ability to reduce the post-prandial spike in blood glucose levels,” stated review coauthor Jay Udani, MD, CEO of Medicus Research.
The review also noted that Phase 2, based on studies done, can be incorporated in food and beverage products “without losing activity or altering the appearance, texture, or taste of food.”
“This published review is another great milestone in our decade-long effort to establish the efficacy and safety of Phase 2,” stated Mitch Skop, senior director of new product development for Pharmachem. “We believe it is one of the most studied and clinically proven dietary ingredients available to help consumers control their weight and resulting health hazards.”
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
Published: May 14th 2024 | Updated: May 15th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.